CU24384B1 - Derivados de n-(3-(6-aminopiridin-4-il)fenil)benzamida como inhibidores de btk - Google Patents
Derivados de n-(3-(6-aminopiridin-4-il)fenil)benzamida como inhibidores de btkInfo
- Publication number
- CU24384B1 CU24384B1 CU2016000078A CU20160078A CU24384B1 CU 24384 B1 CU24384 B1 CU 24384B1 CU 2016000078 A CU2016000078 A CU 2016000078A CU 20160078 A CU20160078 A CU 20160078A CU 24384 B1 CU24384 B1 CU 24384B1
- Authority
- CU
- Cuba
- Prior art keywords
- derivatives
- aminopiridin
- benzamida
- phenyl
- btk inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
<p>La presente invención describe nuevos derivados de pirimidina de fórmula (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>que parecen interactuar con Ia tirosina quinasa de Bruton (Btk). De acuerdo con lo anterior, los derivados novedosos de amino pirimidina pueden ser efectivos en el tratamiento de trastornos autoinmunes, enfermedades inflamatorias, enfermedades alérgicas, enfermedades de las vias aéreas, tales como asma y enfermedad pulmonar obstructiva crónica (EPOC), rechazo de trasplantes, cánceres, por ejemplo tumores sólidos o de origen hematopoyético.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195081 | 2013-11-29 | ||
| PCT/IB2014/066422 WO2015079417A1 (en) | 2013-11-29 | 2014-11-28 | Novel amino pyrimidine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20160078A7 CU20160078A7 (es) | 2016-09-30 |
| CU24384B1 true CU24384B1 (es) | 2019-03-04 |
Family
ID=49674216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2016000078A CU24384B1 (es) | 2013-11-29 | 2014-11-28 | Derivados de n-(3-(6-aminopiridin-4-il)fenil)benzamida como inhibidores de btk |
Country Status (42)
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| SG11201606909RA (en) | 2014-04-07 | 2016-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
| WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| EP4205749A1 (en) | 2014-07-31 | 2023-07-05 | Novartis AG | Subset-optimized chimeric antigen receptor-containing cells |
| AU2015301460B2 (en) | 2014-08-14 | 2021-04-08 | Novartis Ag | Treatment of cancer using GFR alpha-4 chimeric antigen receptor |
| WO2016028896A1 (en) | 2014-08-19 | 2016-02-25 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| AU2015317608B2 (en) | 2014-09-17 | 2021-03-11 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| IL279420B2 (en) | 2014-10-08 | 2024-09-01 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| EP3280795B1 (en) * | 2015-04-07 | 2021-03-24 | Novartis AG | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| AU2016245958B2 (en) | 2015-04-08 | 2021-09-09 | Novartis Ag | CD20 therapies, CD22 therapies, and combination therapies with a CD19 Chimeric Antigen Receptor (CAR) - expressing cell |
| EP4378957A3 (en) | 2015-07-29 | 2024-08-07 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| SI3317301T1 (sl) | 2015-07-29 | 2021-10-29 | Novartis Ag | Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3389712B1 (en) | 2015-12-17 | 2024-04-10 | Novartis AG | Antibody molecules to pd-1 and uses thereof |
| US11413340B2 (en) | 2015-12-22 | 2022-08-16 | Novartis Ag | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy |
| RU2018134771A (ru) | 2016-03-04 | 2020-04-06 | Новартис Аг | Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение |
| CN116769050A (zh) | 2016-07-20 | 2023-09-19 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
| WO2018067992A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| US20200078400A1 (en) | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018223101A1 (en) | 2017-06-02 | 2018-12-06 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CN111050545A (zh) | 2017-06-29 | 2020-04-21 | 朱诺治疗学股份有限公司 | 评估与免疫疗法相关的毒性的小鼠模型 |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| JP7447006B2 (ja) | 2017-11-01 | 2024-03-11 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体 |
| CN111511370A (zh) | 2017-11-01 | 2020-08-07 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体 |
| TWI694995B (zh) * | 2017-11-06 | 2020-06-01 | 美商美國禮來大藥廠 | Btk抑制劑化合物 |
| US20210198372A1 (en) | 2017-12-01 | 2021-07-01 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| CN108069911A (zh) * | 2017-12-14 | 2018-05-25 | 中国药科大学 | 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途 |
| EP3724225A1 (en) | 2017-12-15 | 2020-10-21 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| EP3788369A1 (en) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| CN112203725A (zh) | 2018-06-13 | 2021-01-08 | 诺华股份有限公司 | Bcma嵌合抗原受体及其用途 |
| CA3103943A1 (en) | 2018-07-25 | 2020-01-30 | Novartis Ag | Nlrp3 inflammasome inhibitors |
| JP7439095B2 (ja) | 2018-08-29 | 2024-02-27 | アセルタ・ファーマ・ベスローテン・フェンノートシャップ | ４－｛８－アミノ－３－［（２Ｓ）－１－（ブタ－２－イノイル）－ピロリジン－２－イル］イミダゾ［１，５－ａ］－ピラジン－１－イル｝Ｎ－（ピリジン－２－イル）－ベンズアミドの調製のためのプロセス |
| AU2019372331A1 (en) | 2018-11-01 | 2021-05-27 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| AU2019374103A1 (en) | 2018-11-01 | 2021-05-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) |
| CN113271963A (zh) | 2018-11-16 | 2021-08-17 | 朱诺治疗学股份有限公司 | 给予工程化t细胞以治疗b细胞恶性肿瘤的方法 |
| CA3120869A1 (en) | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| WO2020160050A1 (en) | 2019-01-29 | 2020-08-06 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| WO2020234780A1 (en) | 2019-05-23 | 2020-11-26 | Novartis Ag | Methods of treating asthma using a bruton's tyrosine kinase inhibitor |
| DK3972604T3 (da) * | 2019-05-23 | 2025-09-15 | Novartis Ag | Brutons tyrosinkinasehæmmer til anvendelse ved behandling af kronisk spontan urticaria |
| HRP20241584T1 (hr) * | 2019-05-23 | 2025-01-31 | Novartis Ag | Postupci liječenja sjögrenovog sindroma inhibitorom brutonove tirozin kinaze |
| JP7644027B2 (ja) * | 2019-05-23 | 2025-03-11 | ノバルティス アーゲー | Ｂｔｋ阻害剤の結晶形態 |
| JP7646671B2 (ja) * | 2019-12-23 | 2025-03-17 | バイオジェン・エムエイ・インコーポレイテッド | Ｂｔｋ阻害剤 |
| AU2021251265A1 (en) | 2020-04-10 | 2022-11-03 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen |
| AU2021325431B2 (en) | 2020-08-14 | 2024-01-18 | Novartis Ag | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof |
| WO2022033569A1 (zh) * | 2020-08-14 | 2022-02-17 | 苏州晶云药物科技股份有限公司 | 苯甲酰胺类化合物的晶型及其制备方法 |
| AU2022214490B2 (en) * | 2021-01-26 | 2025-01-02 | Novartis Ag | Pharmaceutical composition |
| WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| AU2022337087A1 (en) * | 2021-09-03 | 2024-03-14 | Novartis Ag | Lou064 for treating multiple sclerosis |
| KR20240122488A (ko) | 2021-12-14 | 2024-08-12 | 노파르티스 아게 | Lou064를 사용한 치료 방법 |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
| KR20250029137A (ko) | 2022-06-22 | 2025-03-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| JP2025525937A (ja) | 2022-08-05 | 2025-08-07 | ジュノー セラピューティクス インコーポレイテッド | Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体 |
| EP4594306A1 (en) | 2022-09-30 | 2025-08-06 | Novartis AG | Synthesis methods and intermediates for the production of remibrutinib |
| JP2026500503A (ja) | 2022-12-13 | 2026-01-07 | ジュノー セラピューティクス インコーポレイテッド | Ｂａｆｆ－ｒおよびｃｄ１９に特異的なキメラ抗原受容体、ならびにその方法および使用 |
| TW202515850A (zh) * | 2023-09-22 | 2025-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 雜芳基類化合物、其製備方法及其在醫藥上的應用 |
| CN117024354B (zh) * | 2023-10-08 | 2023-12-08 | 天津凯莱英制药有限公司 | 瑞米布替尼的制备方法 |
| US20250243170A1 (en) | 2024-01-26 | 2025-07-31 | Novartis Ag | Remibrutinib drug substance and drug product substantially free of nitrosamine impurity |
| WO2025210469A2 (en) | 2024-04-02 | 2025-10-09 | Novartis Ag | Process of preparing remibrutinib substantially free of nitrosamine impurity |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| EP1373554A2 (en) | 2000-10-23 | 2004-01-02 | Bristol-Myers Squibb Company | Modulators of bruton's tyronsine kinase, their identification and use |
| BRPI0115193B1 (pt) | 2000-11-07 | 2016-08-09 | Novartis Ag | derivados de indolilmaleimida, processo para preparação dos mesmos, bem como composição farmacêutica que os compreende |
| AR036053A1 (es) | 2001-06-15 | 2004-08-04 | Versicor Inc | Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| PE20040079A1 (es) | 2002-04-03 | 2004-04-19 | Novartis Ag | Derivados de indolilmaleimida |
| EP1576137A4 (en) | 2002-10-29 | 2010-06-30 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| EP1578411A4 (en) | 2002-12-09 | 2007-05-02 | Univ Texas | PROCESS FOR THE SELECTIVE INHIBITION OF JANUS TYROSINE KINASE3 (JAK3) |
| EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
| CL2004001120A1 (es) | 2003-05-19 | 2005-04-15 | Irm Llc | Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer. |
| US20080207613A1 (en) | 2004-01-12 | 2008-08-28 | Cytopia Research Pty Ltd | Selective Kinase Inhibitors |
| AU2006223409B2 (en) | 2005-03-10 | 2011-07-21 | Gilead Connecticut, Inc. | Certain substituted amides, method of making, and method of use thereof |
| AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| WO2008033858A2 (en) | 2006-09-11 | 2008-03-20 | Cgi Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| CA2680589A1 (en) | 2007-03-14 | 2008-09-18 | Universita' Degli Studi Di Milano - Bicocca | Modulator compounds of the drug resistance in epithelial tumour cells |
| US8426424B2 (en) | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| AU2009265813B2 (en) | 2008-07-02 | 2014-04-10 | F. Hoffmann-La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
| JP5369183B2 (ja) | 2008-07-16 | 2013-12-18 | ファーマサイクリックス，インク． | 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤 |
| US20100261776A1 (en) | 2008-11-07 | 2010-10-14 | The Research Foundation Of State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| SG175287A1 (en) | 2009-04-24 | 2011-11-28 | Hoffmann La Roche | Inhibitors of bruton's tyrosine kinase |
| JP5575275B2 (ja) * | 2010-02-26 | 2014-08-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物のための置換アルキル基含有チエノピリミジン |
| UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| JP6147727B2 (ja) | 2011-04-01 | 2017-06-14 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体 |
| US9580427B2 (en) | 2011-05-17 | 2017-02-28 | The Regents Of The University Of California | Kinase inhibitors |
| KR20140007954A (ko) | 2011-06-10 | 2014-01-20 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| WO2013003629A2 (en) | 2011-06-28 | 2013-01-03 | Pharmacyclics, Inc. | Methods and compositions for inhibition of bone resorption |
| BR112014000314A2 (pt) | 2011-07-08 | 2017-01-10 | Novartis Ag | derivados de pirrolo pirimidina |
| WO2013023084A2 (en) | 2011-08-09 | 2013-02-14 | Fred Hutchinson Cancer Research Center | Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells |
| IL317457A (en) | 2011-10-19 | 2025-02-01 | Pharmacyclics Llc | Use of Bruton's tyrosine kinase inhibitors |
| TW201325593A (zh) | 2011-10-28 | 2013-07-01 | Celgene Avilomics Res Inc | 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法 |
| RU2014126750A (ru) | 2011-12-09 | 2016-01-27 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
| WO2013133367A1 (ja) | 2012-03-09 | 2013-09-12 | カルナバイオサイエンス株式会社 | 新規トリアジン誘導体 |
| CN104662018B (zh) | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| US9133134B2 (en) | 2012-05-16 | 2015-09-15 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| AP2015008203A0 (en) | 2012-08-10 | 2015-01-31 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors |
| CN104822664B (zh) | 2012-10-04 | 2017-01-18 | 犹他大学研究基金会 | 作为酪氨酸受体激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物 |
| US9512084B2 (en) * | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
-
2014
- 2014-11-13 US US14/540,140 patent/US9512084B2/en active Active
- 2014-11-27 AR ARP140104439A patent/AR098549A1/es active IP Right Grant
- 2014-11-27 UY UY0001035858A patent/UY35858A/es active IP Right Grant
- 2014-11-27 JO JOP/2014/0341A patent/JO3314B1/ar active
- 2014-11-28 NO NO14821285A patent/NO3074386T3/no unknown
- 2014-11-28 PL PL20158961.1T patent/PL3689865T3/pl unknown
- 2014-11-28 EA EA201691125A patent/EA031218B1/ru not_active IP Right Cessation
- 2014-11-28 PE PE2016000683A patent/PE20160869A1/es unknown
- 2014-11-28 JP JP2016535053A patent/JP6342495B2/ja active Active
- 2014-11-28 EP EP17191467.4A patent/EP3299368B1/en active Active
- 2014-11-28 EP EP25181626.0A patent/EP4606377A3/en active Pending
- 2014-11-28 TN TN2016000128A patent/TN2016000128A1/en unknown
- 2014-11-28 DK DK17191467.4T patent/DK3299368T3/da active
- 2014-11-28 LT LTEP14821285.5T patent/LT3074386T/lt unknown
- 2014-11-28 DK DK14821285.5T patent/DK3074386T3/en active
- 2014-11-28 MX MX2016006908A patent/MX367911B/es active IP Right Grant
- 2014-11-28 WO PCT/IB2014/066422 patent/WO2015079417A1/en not_active Ceased
- 2014-11-28 ES ES20158961T patent/ES2947770T3/es active Active
- 2014-11-28 PT PT201589611T patent/PT3689865T/pt unknown
- 2014-11-28 AP AP2016009158A patent/AP2016009158A0/en unknown
- 2014-11-28 RS RS20230437A patent/RS64275B1/sr unknown
- 2014-11-28 NZ NZ718835A patent/NZ718835A/en unknown
- 2014-11-28 UA UAA201603623A patent/UA117256C2/uk unknown
- 2014-11-28 PL PL14821285T patent/PL3074386T3/pl unknown
- 2014-11-28 HR HRP20171999TT patent/HRP20171999T1/hr unknown
- 2014-11-28 HU HUE14821285A patent/HUE037588T2/hu unknown
- 2014-11-28 SI SI201431570T patent/SI3299368T1/sl unknown
- 2014-11-28 ES ES17191467T patent/ES2791525T3/es active Active
- 2014-11-28 PT PT171914674T patent/PT3299368T/pt unknown
- 2014-11-28 CU CU2016000078A patent/CU24384B1/es unknown
- 2014-11-28 HR HRP20230585TT patent/HRP20230585T1/hr unknown
- 2014-11-28 EP EP14821285.5A patent/EP3074386B1/en active Active
- 2014-11-28 CN CN201910288376.XA patent/CN110172056B/zh active Active
- 2014-11-28 ES ES23161775T patent/ES3040769T3/es active Active
- 2014-11-28 MY MYPI2016701223A patent/MY179059A/en unknown
- 2014-11-28 MY MYPI2020002915A patent/MY191381A/en unknown
- 2014-11-28 CA CA2926908A patent/CA2926908C/en active Active
- 2014-11-28 HU HUE17191467A patent/HUE049794T2/hu unknown
- 2014-11-28 CN CN201480058515.5A patent/CN105683181B/zh active Active
- 2014-11-28 LT LTEP17191467.4T patent/LT3299368T/lt unknown
- 2014-11-28 EP EP23161775.4A patent/EP4219478B1/en active Active
- 2014-11-28 DK DK20158961.1T patent/DK3689865T3/da active
- 2014-11-28 PT PT148212855T patent/PT3074386T/pt unknown
- 2014-11-28 EP EP20158961.1A patent/EP3689865B1/en active Active
- 2014-11-28 KR KR1020227009823A patent/KR102421388B1/ko active Active
- 2014-11-28 TW TW103141506A patent/TWI652261B/zh active
- 2014-11-28 RS RS20200550A patent/RS60251B1/sr unknown
- 2014-11-28 HU HUE20158961A patent/HUE062248T2/hu unknown
- 2014-11-28 MA MA39055A patent/MA39055B1/fr unknown
- 2014-11-28 ES ES14821285.5T patent/ES2655527T3/es active Active
- 2014-11-28 AU AU2014356069A patent/AU2014356069B2/en active Active
- 2014-11-28 KR KR1020167013830A patent/KR102380539B1/ko active Active
- 2014-11-28 BR BR112016010397-1A patent/BR112016010397B1/pt active IP Right Grant
- 2014-11-28 LT LTEP20158961.1T patent/LT3689865T/lt unknown
- 2014-11-28 SI SI201430536T patent/SI3074386T1/en unknown
- 2014-11-28 SI SI201432031T patent/SI3689865T1/sl unknown
- 2014-11-28 PL PL17191467T patent/PL3299368T3/pl unknown
- 2014-11-28 FI FIEP20158961.1T patent/FI3689865T3/fi active
- 2014-11-28 RS RS20171206A patent/RS56657B1/sr unknown
-
2016
- 2016-04-05 ZA ZA2016/02275A patent/ZA201602275B/en unknown
- 2016-04-06 IL IL244943A patent/IL244943B/en active IP Right Grant
- 2016-04-21 US US15/135,296 patent/US20160235746A1/en not_active Abandoned
- 2016-04-28 PH PH12016500791A patent/PH12016500791A1/en unknown
- 2016-05-03 CL CL2016001055A patent/CL2016001055A1/es unknown
- 2016-05-27 SV SV2016005206A patent/SV2016005206A/es unknown
- 2016-05-27 CR CR20160244A patent/CR20160244A/es unknown
- 2016-06-20 EC ECIEPI201654826A patent/ECSP16054826A/es unknown
-
2017
- 2017-12-22 CY CY20171101345T patent/CY1119705T1/el unknown
-
2018
- 2018-05-08 US US15/974,190 patent/US10457647B2/en active Active
- 2018-05-16 JP JP2018094772A patent/JP6667573B2/ja active Active
-
2019
- 2019-09-16 US US16/571,405 patent/US11180460B2/en active Active
-
2020
- 2020-05-12 HR HRP20200775TT patent/HRP20200775T1/hr unknown
- 2020-05-25 CY CY20201100478T patent/CY1122924T1/el unknown
-
2021
- 2021-10-22 US US17/508,054 patent/US11673868B2/en active Active
-
2023
- 2023-05-01 US US18/309,948 patent/US20230312483A1/en not_active Abandoned
- 2023-06-27 CY CY20231100301T patent/CY1126056T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24384B1 (es) | Derivados de n-(3-(6-aminopiridin-4-il)fenil)benzamida como inhibidores de btk | |
| EA201490229A1 (ru) | Новые пирролопиримидиновые производные | |
| BR112017011798A2 (pt) | 4,6-substituído-pirazolo[1,5-a] pirazinas como inibidores janus cinase | |
| BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
| EA202090291A2 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| CU20160167A7 (es) | Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias | |
| BR112015014034A2 (pt) | inibidores de irak e usos dos mesmos | |
| EA201591689A1 (ru) | НОВЫЕ N-АЦИЛ-(3-ЗАМЕЩЕННЫЕ)-(8-ЗАМЕЩЕННЫЕ)-5,6-ДИГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И МЕТОДЫ ИСПОЛЬЗОВАНИЯ ПРИ РАССТРОЙСТВАХ,ОПОСРЕДОВАННЫХ РЕЦЕПТОРОМ NK-3 | |
| CL2016001543A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas. | |
| BR112014007694A2 (pt) | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)óxi)naftaleno-1-il)ureias como inibidores de p38 map cinase | |
| CL2011000424A1 (es) | Compuestos derivados de (fenil)-amida del acido 7-(heteroaril-metil)-1h-indol-2-carboxilico, inhibidores de map-quinasa p38; composicion farmaceutica; procedimiento para preparar dicha composición ; y uso de los compuestos en el tratamiento de enfermedades de las vias aereas como epoc y asma. | |
| BR112015007974A2 (pt) | compostos de carbamato fenil substituídos | |
| UA110978C2 (uk) | Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak | |
| MX2016001747A (es) | Derivados de difeniloxialquilamina y derivados de ariloxialquilamina, composicion farmaceutica, uso de dicha composicion farmaceutica para tratar, prevenir o inhibir enfermedades inflamatorias pulmonares cronicas y metodo para tratar o prevenir dichas enfermedades. |